Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0406)
Name
DETD-35
Drug Type
Small molecule
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HaCaT cells Normal Homo sapiens CVCL_0038
CCD-966Sk cells Normal Homo sapiens CVCL_U267
A-375 cells Amelanotic melanoma Homo sapiens CVCL_0132
A2058 cells Amelanotic melanoma Homo sapiens CVCL_1059
SK-MEL-2 cells (MEK inhibitor-resistant) cells Melanoma Homo sapiens CVCL_0069
Response regulation Sesquiterpene lactones DET and DETD-35 significantly reprogram this metabolic adaptation and inhibit GPX4 activity to disturb glutathione metabolism and induce ferroptosis. Targeting ferroptosis and GPX4 could be a novel approach to cope with drug resistance in melanoma cancers.
References
Ref 1 Phyto-sesquiterpene lactones DET and DETD-35 induce ferroptosis in vemurafenib sensitive and resistant melanoma via GPX4 inhibition and metabolic reprogramming. Pharmacol Res. 2022 Apr;178:106148. doi: 10.1016/j.phrs.2022.106148. Epub 2022 Feb 26.